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Background: A transsplenic access for the catheterization of the portal venous system to treat a portal vein
thrombosis and/or stenosis entails the risk of intra-abdominal or intrasplenic bleeding complications and has to be
seen as an approach of last resort. This is one of few reported cases in the literature where a transsplenic puncture
tract was successfully embolized using an Amplatzer® vascular plug 4 (8 mm; St. Jude Medical).
Case presentation: This is the case report of a 58 years old Caucasian male patient who had received right sided
extended hemihepatectomy with partial resection of the portal vein due to hilar cholangiocarcinoma three years
ago. The patient suffered from portal hypertension with difficult controllable bleeding of esophageal varices due to
chronically progressive thrombosis of the portal vein caused by chronic anastomosis stenosis of the reconstructed
left portal vein branch (confirmed in a Magnetic Resonance Imaging (MRI) examination 6 months after the portal
vein reconstruction). A transsplenic access (6 French) was chosen to allow recanalization of the portal vein,
stent-angioplasty of the anastomosis and coiling of the gastric varices. The transsplenic tract was successfully
embolized with an Amplatzer® Vascular Plug 4 and gelfoam pledgets.
Conclusion: Amplatzer® Vascular plugs in combination with gelatin sponges can be used to efficiently and
precisely seal transsplenic puncture sites.
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Several approaches are available for the catheterization
of the portal venous system: the percutaneous transhe-
patic approach, the direct catheterization of a mesenteric
vein via mini laparotomy, the use of a transjugular intra-
hepatic stent shunt (TIPSS) as well as access over a re-
canalization of the umbilical vein. Besides these options,
the transsplenic approach provides a straightforward
way (in the absence of a tortuous splenic vein) to access
the portal venous system as well as gastric or oesophageal
varices [1]. Nevertheless, a transsplenic access route has to
be seen as an approach of last resort and complications in
the form of intra-abdominal or intrasplenic bleeding
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unless otherwise stated.We report a case of a successful recanalization of a
chronic portal vein thrombosis via a transsplenic access
route in a patient with stenosis of the reanastomized
portal vein after extended right hemihepatectomy and
reconstructed left portal vein. Similar to a recently pub-
lished case by Dollinger et al., an Amplatzer® plug 4
(8 mm; St. Jude Medical) in combination with gelfoam
pledgets was successfully used to seal the transsplenic
access site [2].
Case presentation
A 58 years old Caucasian patient with a past medical
history of a hilar cholangiocarcinoma (Bismuth stage IV)
had received a right sided extended hemihepatectomy
(segments 1, 4–8) with a reconstruction of the left prox-
imal portal vein using a short, approximately 4 cm long
allogenic iliac artery interposition graft three years earlier.
Up to now no cancer recurrence was noted. However, due
to a stenosis of the portal vein anastomosis which wasThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and diagnosed in a MRI examination 6 months after the
operation (as demonstrated in Additional file 1: Figure S1)
a chronically progressive thrombosis of the portal vein
and consecutive portal hypertension had developed. At
the time of the intervention, the patient suffered from
recurrent bleeding of esophageal varices. No operative
treatment options such as the creation of a porto-venous
shunt or the revision of the anastomosis were feasible due
to the postoperative situs.
A pre-interventional contrast-enhanced CT of the ab-
domen (Figure 1A-C) demonstrates the situs after
right sided hemihepatectomy, ascites, and the cavernous
portal vein occlusion with extension of the thrombosis
to the portal vein confluence as well as huge esophago-
gastric varices mainly arising from the left gastric vein.
Laboratory data showed thrombocytopenia (54.000/μl), a
slightly elevated INR value of 1.4 and a decreased
hemoglobin level of 9.7 g/dL. ALT (12 U/l), NH3 (36 mg/dl)
and total bilirubin (1.1 mg/dl) were unremarkable prior to
the intervention.
Due to the right-sided extended hemihepatectomy and
the narrow poststenotic left portal venous branches
catheterization of the portal venous system via a transju-
gular intrahepatic stent shunt (TIPSS) or a percutaneous
transhepatic approach were considered inappropriate
and a transsplenic approach was chosen. Under local
anesthesia, a sonographically guided puncture (21 G fine
needle) of a caudal hilar splenic vein was performed.
Using Seldinger technique, a 0.018“ wire (V18 Control
wire; Boston Scientific) and support catheter (TrailBlazer™,
a 4 F catheter tapered down to 0.018 inch; ev3 Endovascu-
lar) were introduced. The following splenoportography
(Figure 2A, B; note the faint contrast of the initial sple-
noportogram due to small end hole of the TrailBlazer™
catheter) confirmed a complete portal vein occlusion andFigure 1 Pre-interventional Contrast-enhanced CT of the abdomen: A, B, C
venous phase images demonstrate the postoperative situs after hemihepat
confluence, ascites and splenomegaly.showed massive esophageal and gastric varices. The portal
vein occlusion could not be traversed using the 0.018”
wire and the support catheter, thus a 4 F sheath and an
JR4 configured 4 F angiography catheter (Cordis Corpor-
ation) with an hydrophilic guide wire (Terumo® 0.035”,
Terumo Corp.) were advanced to improve controllability
and pushability. After successful crossing of the portal
vein occlusion, direct pressure measurements in the
splenic vein showed a pressure of 32 mmHg, while
15 mmHg could be measured in the intrahepatic portal
vein branches. After the initial angioplasty of the portal
vein anastomosis and preceding segments (the main por-
tal vein below the graft) with a 7 mm angioplasty balloon
(Passeo-18; Biotronic) marked recoiling was observed.
After upgrading the 4 F sheath to 6 F, the main portal vein
was dilated with a 10 mm angioplasty balloon (Armada™
35; Abbott Vascular). Due to a still evident recoiling,
stent-angioplasty of the anastomosis with a 10/60 mm
nitinol stent (Protégé GPS™; ev3 Endovascular) and post
dilatation with a 10 mm balloon were performed. The
following splenoportography showed mobile parts of the
thrombus proximal to the implanted stent making a dual
stent extension with a 10/60 mm (Protégé GPS™; ev3
Endovascular) and a 12/40 mm nitinol stent (Sinus-Super-
Flex™; OptiMed) to preceding portal vein segments neces-
sary. The finally acquired splenoportography after coiling
of the gastric varices demonstrated a satisfying result with
a fast runoff of the applied contrast media in the intrahe-
patic portal vein branches (Figure 3A). Obtained pressure
values after stent angioplasty showed 32 mmHg in the
splenic vein and 22 mmHg in intrahepatic portal vein
branches, but due to the fast runoff of the applied contrast
media no further angioplasty was carried out.
At the end of the intervention, the transsplenic tract
was embolized with an Amplatzer® plug 4 (8 mm; St.
Jude Medical) (Figure 3B) as well as gelfoam pledgets.Coronal (arrows are pointing to the occluded portal vein) and axial
ectomy, the cavernous portal vein occlusion with extension to the
Figure 2 Baseline splenoportography: A, B Initial splenoportogram with an advanced support catheter (TrailBlazer™ 0.018 inch; ev3 Endovascular)
confirmed a complete portal vein occlusion and showed massive esophageal and gastric varices.
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described by Dollinger et al. in a recent published case
series [2]: While the Amplatzer® plug was fixed in the
desired position approximately 2 cm medial to the
splenic capsule, the 6 F sheath was slowly pulled back.
Contrast medium was delivered over the sheath to verify
the correct position of the Amplatzer® plug before it was
released. Due to the poor condition of the patient and
the increased pressure values in the splenic vein, gel-
foam pledgets were additionally delivered via the sheath
as it was removed.
A post-interventional ultrasound examination showed
no evidence of a hemoperitoneum or a perisplenic or
splenic hematoma formation. Nevertheless, as an expec-
ted minor complication leakage of a larger quantity of
ascites at the puncture site occurred in the first hours
after the intervention. ALT (7 U/l), NH3 (30 mg/dl) and
total bilirubin (0.6 mg/dl) remained unremarkable the
following days and no bleeding of the esophageal varices
reoccurred after the intervention. An esophageal gastro-
duodenoscopy was performed 5 months later and could
not detect esophageal varices. Regular follow-up ultra-
sound examinations were carried out on an outpatientFigure 3 Splenoportography after stent extension and transsplenic tract em
demonstrated a fast runoff of the applied contrast media in the intrahepat
after Coil-embolization. B Transsplenic tract embolization with an Amplatzer®
the sheath as it was removed.basis and demonstrated a patent portal vein Three years
after the recanalization of the portal vein a PET-CT was
performed due to recurrent cholangitis (Figure 4), which
showed no malignant recurrence, demonstrated a patent
portal vein with left hepatic lobe hypertrophy (Figure 4)
and the Amplatzer® vascular plug within the spleen
(Figure 4C).
Conclusion
In this patient, a thrombotic stenosis of the recon-
structed left portal vein anastomosis (diagnosed in a
MRI examination 6 months after the operation (as dem-
onstrated in Additional file 1: Figure S1) after right-sided
extended hemihepatectomy was the triggering reason for
the portal hypertension. In general, the exact cause of a
portal vein thrombosis often remains unclear although
risk factors such as malignancy, thrombophilic syn-
dromes, myeloproliferative disorders, pregnancy, local
inflammation and infection are known [3]. Even though
less than 3% of all cases of portal hypertension are
caused by portal vein thrombosis, a population-based
study by Ögren et al. has suggested that the prevalence
of portal vein thrombosis might be underestimated asbolization at the end of the intervention: A Final splenoportogram
ic portal vein branches and a reduced blood flow to the gastric varices
plug 4 (8 mm; St. Jude Medical) as well as gelfoam pledgets delivered via
Figure 4 Contrast-enhanced PET-CT of the abdomen 3 years post-interventional: A, B, C Coronal and axial venous phase images demonstrate a
patent portal vein with stents in situ, a left hepatic lobe hypertrophy and the Amplatzer® vascular plug (marked with an arrow in C) within the spleen.
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tients with cirrhosis and hepatic cancer as well as a life-
time risk of 1% in the general population [4].
In the context of postoperative complications, Yoshiya
et al. presented the first larger study on postoperative
portal vein thrombosis after hepatectomy and concluded
that this complication is not rare and occurred in 9.1%
of all their investigated cases [5]. Furthermore, the
authors of this article concluded that besides of above
mentioned risk factors the duration of clamping the hepa-
toduodenal ligament (“Pringle maneuver”) represented
another significant risk factor [5].
Clinically, an acute (non-cavernous) form with abdom-
inal pain, fever, nausea, ascites and variceal bleeding can
be distinguished from a chronic (cavernous) form with
symptoms of portal hypertension lead to such as ascites,
portosystemic collateralization with formation of varices
and/ or hepatic encephalopathy [6]. The therapeutic
management of an acute portal vein thrombosis is based
on the clinical presentation of the patient and includes
systemic anticoagulation as well as local thrombolysis,
mechanical thrombectomy, angioplasty, a combination
of these or the creation of a transjugular intrahepatic
portosystemic stent shunt (TIPSS) in more symptomatic
patients (for more detailed information please refer to
the review by Lang et al.) [7].
On the contrary, there is less evidence in the literature
regarding the best therapeutic approach in symptomatic
patients with a cavernous transformation of the portal
vein although several studies have successfully demon-
strated the feasibility of a endovascular portal vein recana-
lization using different access routes [1,6,8].
Especially in the case of portal hypertension, transsple-
nic access for the catheterization of the portal venous
system entails the risk of intra-abdominal or intrasplenic
bleeding complications and has to be seen as an ap-
proach of last resort. Gong et al. reported that in a series
of 18 patients, transsplenic access using a 5 F sheath led
to a hemoperitoneum in two patients while Liang et al.
experienced three cases of significant bleeding in a series
of 17 patients [9,10]. Nevertheless, Probst et al. first re-
ported a simple technique to avoid these bleedingcomplications from the puncture site by plugging the
splenic access tract with compressed gelatin sponges in
1978 [11]. Nowadays different embolization techniques
have been developed and subsequently reduced the risk
of splenic hemorrhage [12]. For example Chu et al. used
4 to 9 F sheaths to access the splenic vein and reported
no bleeding complications in nine patients by using differ-
ent coils in combination with a mixture of n-butyl cyanoa-
crylat (Histoacryl) and lipiodol for the embolization of the
splenic puncture site [1]. Using a similar embolization
technique Zhu et al. reported in a larger clinical study on
46 patients, 3 cases with major and 7 cases with minor
bleeding complications after a percutaneous transsplenic
approach with 5 F sheaths [8]. In a recent published case
series (5 patients) Dollinger et al. used Amplatzer® vascular
plugs 2 and 4 (4 – 8 mm) to embolize large bore (6 – 10 F
sheaths) and/or short transparenchymal hepatic (4 cases)
or splenic (1 case) puncture tracts [2]. Although, the only
patient with a transsplenic access in this study died 21 days
after the intervention due to pneumonia, the author did
not experience bleeding complications from the hepatic
and splenic puncture tracts. As a minor complication
one patient developed a postinterventional focal liver
abscess adjacent to the Amplatzer® plug, so that the
authors recommended a periinterventional antimicrobial
prophylaxis.
In summary, low-profile sheaths or catheters make the
occurrence of life-threatening bleeding complications
after a transsplenic or transhepatic access highly improb-
able. In the presented case a 6 F sheath had to be used
due to the required stent implantation in the portal vein.
Consecutively, the splenic access tract was embolized
using an Amplatzer® Vascular Plug 4 (8 mm; St. Jude
Medical) in an off-label scenario in combination with gel-
atin sponges, which allowed efficient and precise sealing
of the splenic puncture site.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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Additional file 1: Figure S1. Contrast-enhanced MRI using a T1-w 3D
fast low angle shot (FLASH) fat supressed sequence 6 months postoperative:
A, B Consecutive axial portal venous phase MRI images demonstrating a
stenosis of the reconstructed left portal vein anastomosis (arrows are
pointing to the anastomotic stenosis). Note that susceptibility artefacts are
caused by postoperative clips at the anastomosis site.
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